CN101874020B - 作为毒蕈碱受体激动剂的哌啶衍生物 - Google Patents

作为毒蕈碱受体激动剂的哌啶衍生物 Download PDF

Info

Publication number
CN101874020B
CN101874020B CN2008801155657A CN200880115565A CN101874020B CN 101874020 B CN101874020 B CN 101874020B CN 2008801155657 A CN2008801155657 A CN 2008801155657A CN 200880115565 A CN200880115565 A CN 200880115565A CN 101874020 B CN101874020 B CN 101874020B
Authority
CN
China
Prior art keywords
piperidin
methyl
hexahydro
benzimidazol
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2008801155657A
Other languages
English (en)
Chinese (zh)
Other versions
CN101874020A (zh
Inventor
程云兴
罗雪红
维杰亚拉特南·桑萨库玛
米洛斯劳·J·托马斯泽夫斯基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN101874020A publication Critical patent/CN101874020A/zh
Application granted granted Critical
Publication of CN101874020B publication Critical patent/CN101874020B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
CN2008801155657A 2007-09-11 2008-09-09 作为毒蕈碱受体激动剂的哌啶衍生物 Expired - Fee Related CN101874020B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97128807P 2007-09-11 2007-09-11
US60/971,288 2007-09-11
PCT/GB2008/050802 WO2009034380A1 (en) 2007-09-11 2008-09-09 Piperidine derivatives as agonists of muscarinic receptors

Publications (2)

Publication Number Publication Date
CN101874020A CN101874020A (zh) 2010-10-27
CN101874020B true CN101874020B (zh) 2012-11-07

Family

ID=40011174

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008801155657A Expired - Fee Related CN101874020B (zh) 2007-09-11 2008-09-09 作为毒蕈碱受体激动剂的哌啶衍生物

Country Status (18)

Country Link
US (1) US8119661B2 (cg-RX-API-DMAC7.html)
EP (1) EP2197843B1 (cg-RX-API-DMAC7.html)
JP (1) JP2010539151A (cg-RX-API-DMAC7.html)
KR (1) KR20100052528A (cg-RX-API-DMAC7.html)
CN (1) CN101874020B (cg-RX-API-DMAC7.html)
AR (1) AR071245A1 (cg-RX-API-DMAC7.html)
AT (1) ATE539056T1 (cg-RX-API-DMAC7.html)
AU (1) AU2008299604A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0816331A2 (cg-RX-API-DMAC7.html)
CA (1) CA2699286A1 (cg-RX-API-DMAC7.html)
CL (1) CL2008002689A1 (cg-RX-API-DMAC7.html)
ES (1) ES2377772T3 (cg-RX-API-DMAC7.html)
MX (1) MX2010002584A (cg-RX-API-DMAC7.html)
PE (1) PE20091090A1 (cg-RX-API-DMAC7.html)
RU (1) RU2010110036A (cg-RX-API-DMAC7.html)
TW (1) TW200924766A (cg-RX-API-DMAC7.html)
UY (1) UY31334A1 (cg-RX-API-DMAC7.html)
WO (1) WO2009034380A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200813018A (en) * 2006-06-09 2008-03-16 Astrazeneca Ab Novel compounds
TW200815405A (en) * 2006-06-09 2008-04-01 Astrazeneca Ab Novel compounds
US20090221642A1 (en) * 2008-03-03 2009-09-03 Astrazeneca Ab Muscarinic receptor agonists, compositions, methods of treatment thereof, and processes for preparation thereof-176
US20090275574A1 (en) * 2008-05-05 2009-11-05 Astrazeneca Ab Novel compounds-300
PT2780015T (pt) 2011-11-18 2017-03-23 Heptares Therapeutics Ltd Agonistas de recetor muscarínico m1
US9266857B2 (en) 2012-09-18 2016-02-23 Heptares Therapeutics Limited Bicyclic AZA compounds as muscarinic M1 receptor agonists
ES2694299T3 (es) 2013-02-07 2018-12-19 Heptares Therapeutics Limited Carboxilatos de piperidin-1-ilo y azepin-1-ilo como agonistas del receptor muscarínico M4
GB2519470A (en) * 2013-09-18 2015-04-22 Heptares Therapeutics Ltd Bicyclic aza compounds as muscarinic M1 receptor agonists
PL3406609T3 (pl) * 2014-02-06 2024-11-25 Nxera Pharma Uk Limited Związki aza-bicykliczne jako agoniści receptorów muskarynowych
GB201404922D0 (en) 2014-03-19 2014-04-30 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201513743D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201519352D0 (en) 2015-11-02 2015-12-16 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201617454D0 (en) 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
GB201810239D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819961D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819960D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB202020191D0 (en) 2020-12-18 2021-02-03 Heptares Therapeutics Ltd Pharmaceutical compounds

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997016192A1 (en) * 1995-10-31 1997-05-09 Merck & Co., Inc. Muscarine antagonists
WO2005042517A2 (en) * 2003-11-03 2005-05-12 Schering Corporation Bipiperidinyl derivatives useful as inhibitors of chemokine receptors
WO2007036711A1 (en) * 2005-09-30 2007-04-05 Glaxo Group Limited BENZIMIDAZOLONES WHICH HAVE ACTIVITY AT Ml RECEPTOR

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0029707B1 (en) 1979-11-21 1984-02-01 Kyowa Hakko Kogyo Co., Ltd Novel piperidine derivatives, method for the preparation thereof and pharmaceutical compositions containing them
DE4302051A1 (de) 1993-01-26 1994-07-28 Thomae Gmbh Dr K 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE69430483D1 (de) 1993-07-16 2002-05-29 Merck & Co Inc Benzoxazinon- und Benzopyrimidinon- piperidinyl-Verbindungen als tokolytische Oxytocin-Rezeptor-Antagonisten
JP2002515008A (ja) 1994-10-27 2002-05-21 メルク エンド カンパニー インコーポレーテッド ムスカリン・アンタゴニスト
US5756508A (en) * 1995-10-31 1998-05-26 Merck & Co., Inc. Muscarine antagonists
US5756497A (en) * 1996-03-01 1998-05-26 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
CA2262818A1 (en) 1996-09-10 1998-03-19 Dr. Karl Thomae Gesellschaft Mit Beschrankter Haftung Modified amino acids, pharmaceuticals containing these compounds and methods for their production
JPH10158192A (ja) * 1996-10-03 1998-06-16 Eisai Co Ltd 移植片対宿主疾患(gvhd)の治療および臓器移植時の移植片拒絶反応抑制のための医薬組成物
SE9704546D0 (sv) 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
AU2307999A (en) 1997-12-23 1999-07-12 Alcon Laboratories, Inc. Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
DK1049689T3 (da) 1998-01-19 2002-07-22 Pfizer 4-(2-keto-1-benzimidazolinyl)piperidinderivater som ORL1-receptoragonister
MA26659A1 (fr) * 1998-08-06 2004-12-20 Pfizer Dérivés de benzimidazole nouveaux, compositions pharmaceutiques les contenant et procédé pour leur préparation.
JP2000323278A (ja) 1999-05-14 2000-11-24 Toray Ind Inc 発光素子
WO2001027104A1 (en) 1999-10-13 2001-04-19 Banyu Pharmaceutical Co., Ltd. Substituted imidazolidinone derivatives
SE9904652D0 (sv) 1999-12-17 1999-12-17 Astra Pharma Prod Novel Compounds
EP1309593B1 (en) 2000-08-14 2006-03-15 Ortho-McNeil Pharmaceutical, Inc. Substituted pyrazoles
JP2002302675A (ja) 2001-04-06 2002-10-18 Fuji Photo Film Co Ltd 液晶組成物、それを用いた液晶素子およびアゾ化合物
NZ540233A (en) 2001-04-18 2007-02-23 Euro Celtique Sa Nociceptin analogs for the treatment of pain
AU2002338424B2 (en) * 2001-04-18 2005-04-21 Euro-Celtique S.A. Benzimidazolone compounds
CA2444595A1 (en) 2001-04-20 2002-10-31 Banyu Pharmaceutical Co., Ltd. Benzimidazolone derivatives
AR036366A1 (es) * 2001-08-29 2004-09-01 Schering Corp Derivados de piperidina utiles como antagonistas de ccr5, composiciones farmaceuticas, el uso de dichos derivados para la fabricación de un medicamento y un kit
WO2004089942A2 (en) 2001-10-02 2004-10-21 Acadia Pharmaceuticals Inc. Benzimidazolidinone derivatives as muscarinic agents
WO2003037890A2 (en) 2001-11-01 2003-05-08 Icagen, Inc. Piperidines
PL373889A1 (en) 2002-04-18 2005-09-19 Schering Corporation (1-4-piperidinyl)benzimidazole derivatives useful as histamine h3 antagonists
AU2003245565B2 (en) 2002-06-17 2008-01-03 Banyu Pharmaceutical Co., Ltd. Ophthalmic compositions for treating ocular hypertension
WO2004069828A1 (ja) 2003-02-04 2004-08-19 Mitsubishi Pharma Corporation ピペリジン化合物およびその医薬用途
ES2290743T3 (es) 2003-04-30 2008-02-16 The Institutes For Pharmaceutical Discovery, Llc Heteroarilos sustituidos como inhibidores de las proteina-tirosina fosfatasas.
MXPA06007054A (es) 2003-12-19 2007-04-17 Elixir Pharmaceuticals Inc Metodos para tratar una enfermedad.
US20050228023A1 (en) 2003-12-19 2005-10-13 Sri International Agonist and antagonist ligands of the nociceptin receptor
JP2008501031A (ja) 2004-05-28 2008-01-17 バーテックス ファーマシューティカルズ インコーポレイテッド ムスカリン受容体のモジュレーター
TWI400232B (zh) 2004-09-13 2013-07-01 Ono Pharmaceutical Co 含氮雜環衍生物及以該含氮雜環衍生物為有效成分之藥劑
CA2581930A1 (en) 2004-09-27 2006-04-06 Jane Trepel Modulating mxa expression
WO2006038594A1 (ja) 2004-10-04 2006-04-13 Ono Pharmaceutical Co., Ltd. N型カルシウムチャネル阻害薬
WO2006130469A1 (en) 2005-05-27 2006-12-07 Oregon Health & Science University Stimulation of neurite outgrowth by small molecules
TW200813018A (en) * 2006-06-09 2008-03-16 Astrazeneca Ab Novel compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997016192A1 (en) * 1995-10-31 1997-05-09 Merck & Co., Inc. Muscarine antagonists
WO2005042517A2 (en) * 2003-11-03 2005-05-12 Schering Corporation Bipiperidinyl derivatives useful as inhibitors of chemokine receptors
WO2007036711A1 (en) * 2005-09-30 2007-04-05 Glaxo Group Limited BENZIMIDAZOLONES WHICH HAVE ACTIVITY AT Ml RECEPTOR

Also Published As

Publication number Publication date
EP2197843B1 (en) 2011-12-28
AR071245A1 (es) 2010-06-09
UY31334A1 (es) 2009-04-30
ATE539056T1 (de) 2012-01-15
CA2699286A1 (en) 2009-03-19
AU2008299604A1 (en) 2009-03-19
BRPI0816331A2 (pt) 2015-04-14
PE20091090A1 (es) 2009-08-27
CN101874020A (zh) 2010-10-27
JP2010539151A (ja) 2010-12-16
US20090076078A1 (en) 2009-03-19
CL2008002689A1 (es) 2009-11-27
EP2197843A1 (en) 2010-06-23
KR20100052528A (ko) 2010-05-19
ES2377772T3 (es) 2012-03-30
TW200924766A (en) 2009-06-16
MX2010002584A (es) 2010-03-26
RU2010110036A (ru) 2011-10-20
WO2009034380A1 (en) 2009-03-19
US8119661B2 (en) 2012-02-21

Similar Documents

Publication Publication Date Title
CN101874020B (zh) 作为毒蕈碱受体激动剂的哌啶衍生物
US20090221567A1 (en) Muscarinic receptor agonists, compositions, methods of treatment thereof, and processes for preparation thereof 177
US7956069B2 (en) Compounds
AU2007256014B2 (en) Muscarinic receptor agonists that are effective in the treatment of pain, Alzheimer's disease and schizophrenia
CN101472917A (zh) 作为大麻素1(cb1)受体配体的苯并咪唑5-磺酰胺衍生物
CN102015688A (zh) 毒蕈碱性受体激动剂、组合物、治疗方法及其制备方法
US20090275574A1 (en) Novel compounds-300

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20121107

Termination date: 20130909